Last Updated on December 19, 2024 by The Health Master
GMP Audit
Alembic Pharmaceuticals, a leading pharmaceutical company, has successfully cleared a crucial hurdle in its global expansion plans by completing GMP audit.
The company recently announced that its API-II facility at Panelav has successfully passed the Good Manufacturing Practices audit (GMP audit) conducted by the Brazilian Health Regulatory Agency (ANVISA).
ANVISA GMP Approval: A Significant Milestone
The ANVISA GMP approval is a significant milestone for Alembic Pharmaceuticals.
This certification validates the company’s commitment to quality, safety, and regulatory compliance.
By achieving this certification, Alembic can now expand its market reach in Brazil, a key market for pharmaceutical products.
Key Takeaways
- Successful ANVISA GMP Audit: Alembic’s API-II facility at Panelav successfully completed the rigorous ANVISA GMP audit.
- Expanded Market Access: The approval will enable Alembic to export its high-quality APIs to the Brazilian market.
- Strengthened Global Presence: This achievement further solidifies Alembic’s position as a global pharmaceutical player.
About Alembic Pharmaceuticals
Alembic Pharmaceuticals is a renowned pharmaceutical company with a strong focus on research and development, manufacturing, and marketing of a diverse range of pharmaceutical products.
The company’s product portfolio includes generic drugs, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products.
With a global presence spanning over 75 countries, Alembic is dedicated to providing affordable and high-quality medicines to patients worldwide.
The company’s therapeutic focus areas include cardiovascular, anti-infective, pain management, and oncology.
By securing ANVISA GMP approval, Alembic Pharmaceuticals has taken a significant step towards strengthening its global presence and delivering high-quality medicines to patients worldwide.
Q: What is ANVISA GMP?
A: ANVISA GMP is a regulatory standard set by the Brazilian Health Regulatory Agency (ANVISA) to ensure the quality, safety, and efficacy of pharmaceutical products manufactured in Brazil.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Key Notes on Revised Schedule M: Compilation
Important short notes for Industry and Regulators
CDSCO Guidelines on Drug Recall
Quality Assurance Vs Quality Control in the Pharma Industry
Major FDA audit findings about Equipment and Instruments
Understanding GMP, cGMP, and WHO-GMP
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Key Notes on Revised Schedule M: Point No. 3 – Good Manufacturing Practice (GMP)
Indian Pharma Industry to face New GMP Regulations Compliance
9th Advanced GMP Workshop organised: IPA
Gujarat FDCA and IDMA Join Forces for GMP Compliance Training
Venus Remedies gets GMP certificate from Libya: A Gateway to African Markets
CDSCO approval granted to market Insulin Inhalation Powder
DCGI to inaugurate AIPAC Event: A Boon for Indian Pharmaceutical
Key Notes on Revised Schedule M: Point No. 5 – Qualification and validation
CDSCO directs expedited Approval of Rare Disease Drugs and Medical Devices
CDSCO approves Robotic System for Telesurgery
MN Sridhar has been appointed as Director of Drug Control Administration: Tamil Nadu
NPPA approves price increase for 11 Drugs
Four arrested for supplying Spurious Drugs to Maharashtra Hospital
Key Notes on Revised Schedule M: Point No. 4 – Sanitation and Hygiene
Wearable Medical device: The Future of Heart Health Monitoring
